DataMEDS AI, Inc. (MEDS) Earnings History
Net Loss3 years of earnings data (2023–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
DataMEDS AI, Inc. (MEDS) Earnings Overview
As of November 21, 2026, DataMEDS AI, Inc. (MEDS) reported trailing twelve-month net income of -$43M, reflecting -1000.0% year-over-year growth. The company earned $-10.95 per diluted share over the past four quarters, with a net profit margin of -433.9%.
Looking at the long-term picture, MEDS's historical earnings data spans multiple years. The company achieved its highest annual net income of -$3M in fiscal 2023.
DataMEDS AI, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including HSIC ($421M net income, 3.0% margin), ACH (-$172M net income, -39.8% margin), HCSG ($105M net income, 3.2% margin), MEDS has room to improve margins relative to the peer group. Compare MEDS vs HSIC →
MEDS Earnings vs Peers
Earnings metrics vs comparable public companies
MEDS Historical Earnings Data (2023–2025)
3 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$101M | -1377.1% | -$81M | $-71.50 | -433.9% | -347.9% |
| 2024 | -$7M | -136.8% | -$6M | $-6.50 | -37.8% | -33.9% |
| 2023 | -$3M | - | -$3M | $-3.00 | - | - |
Download Data
Export MEDS earnings history in CSV or JSON format
Free sign-in required to download data
MEDS Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
3+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
MEDS — Frequently Asked Questions
Quick answers to the most common questions about buying MEDS stock.
What is MEDS earnings per share (EPS)?
MEDS trailing twelve-month (TTM) diluted EPS is $-10.95, reflecting -1000.0% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2023 to 2025 is available in the table on this page.
What is DataMEDS AI, Inc.'s net income?
DataMEDS AI, Inc. (MEDS) trailing twelve-month net income is $-43M as of 2025. Earnings declined -1000.0% year-over-year.
Is MEDS profitable?
MEDS is not currently profitable on a TTM basis, reporting a net loss of $-43M. Net margin is -433.9%. Investors should monitor for a return to profitability.
What is MEDS's earnings growth rate?
MEDS compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2023 to 2025.
What are MEDS's profit margins?
DataMEDS AI, Inc. net profit margin is -433.9%, operating margin is -347.9%, and gross margin is -41.3%. Below-average margins reflect competitive or cost pressures. Return on Equity is N/A.
Is MEDS growing earnings?
MEDS earnings are declining — EPS fell -1000.0% year-over-year. TTM net income dropped to $-43M. This contrasts with the 5-year CAGR of N/A.
What was MEDS's best earnings year?
DataMEDS AI, Inc.'s highest annual net income on record is $-3M, achieved in fiscal year 2023. Earnings history on this page spans 2023 to 2025 and includes all annual and quarterly figures.
What were MEDS's earnings last quarter?
MEDS's most recent reported quarter was Q3 2026. Net income was $11M with diluted EPS of $2.67. For a full breakdown of all quarters, see the quarterly earnings table on this page.